
Address
Want more information? Contact a representative below.
Laboratory Representative
(P)
Description
The U.S. Army Medical Research and Development Command (USAMRDC) is the Army's medical materiel developer. The Command has four major Core Capabilities:
-
Shape future medical solutions through research, advanced technology, and partnerships;
- Execute streamlined medical logistics, facilities and acquisition management;
- Develop, integrate, acquire and sustain medical IM/IT solutions; and
- Provide best business and program management solutions.
Mission
The USAMRDC is the executive or lead agency responsible for:
- Military Human Immunodeficiency Virus (HIV) R&D Program (Acquired Immune Deficiency Syndrome (AIDS))
- Military Infectious Diseases Research Program (MIDRP)
- Global Emerging Infections Surveillance and Response System (GEIS)
- Use of Investigational New Drugs for Force Health Protection
- DOD Food and Nutrition Research, Development, Test, Evaluation, and Engineering Program
- Combat Dentistry Research Program
- Gulf War Illnesses/Force Health Protection Research Program
- Peer Reviewed Medical Research Program (PRMRP)
The USAMRDC's expertise in these critical areas helps establish and maintain the capabilities required by the Army to fight and win on the battlefield.
Technology Disciplines
SUMMARY: In accordance with applicable laws and regulations, announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license.
Dr. Paul Michaels, Office of Research & Technology Applications, (301) 619-4145. For patent issues, Ms. Leigh Callander, Supervisory Patent Attorney, (301) 619-7808.
SUPPLEMENTARY INFORMATION: In accordance with 35 U.S.C. 209 (e) and 37 CFR 404.7 (a)(1)(i), announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license to Celdara Medical, LLC, having its principle place of business at 16 Cavendish Ct. Lebanon, NH 03766. The license agreement includes following U.S. Patents and U.S. Patent Applications:
U.S. Patent No. 9,346,875 for an invention titled “Therapy for Filovirus Infection” co-owned with the Albert Einstein College of Medicine; and The Governing Council of the University of Toronto, USAMRDC Reference Number 15-10;
U.S. Patent No. 10,081,669; for an invention titled “Therapy for Filovirus Infection” co-owned with the Albert Einstein College of Medicine; and The Governing Council of the University of Toronto, USAMRDC Reference Number 15-10;
U.S. Patent No. 10,435,461; for an invention titled “Therapy for Filovirus Infection” co-owned with the Albert Einstein College of Medicine; and The Governing Council of the University of Toronto, USAMRDC Reference Number 15-10;
U.S. Patent No. 10,875,907 for an invention titled “Filovirus Antibody” co-owned with the Albert Einstein College of Medicine and The Governing Council of the University of Toronto, USAMRDC Reference Number 15-10; and
U.S. Patent Application No. 17/611,391 for an invention titled “Antibodies to Sudan and Ebola Virus” co-owned with the French Ministry of Defense, USAMRDC Reference Number 18-16.
Androgen receptor (AR) plays a critical role in prostate cancer. Length of AR’s N-terminal glutamine (Q) tract has been associated with disease risk, and AR somatic mutation may influence disease progression. To study the basis for these effects in an animal model, the mouse AR gene was converted to the human sequence, using homologous recombination in embryonic stem cells.
In accordance with applicable laws and regulations, announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license.
Dr. Paul Michaels, Director of the Office of Research & Technology Applications, (301) 619-4145. For patent issues, Ms. Leigh Callander, Supervisory Patent Attorney, (301) 619-7808.
In accordance with 35 U.S.C. 209 (e) and 37 CFR 404.7 (a)(1)(i), announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license to “purified, recombinant, catalytically inactive botulinum neurotoxin holoproteins (ciBoNT) representing serotypes A-F produced in transgenic strains of the methylotrophic yeast Pichia pastoris, and Pichia pastoris cell lines expressing the same ciBoNTs, in their capacity as producers of the ciBoNTs only” to Mapp Biopharmaceutical, Inc., having its principal place of business at 6160 Lusk Blvd. # C200, San Diego, CA 92121.
Anyone wishing to object to grant of this license can file written objections along with supporting evidence, if any, within 15 days from the date of this publication. Written objections are to be filed with the Director, Office of Research and Technology Applications (see ADDRESSES).
In accordance with applicable laws and regulations, announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license.
Mr. Paul Michaels, Office of Research & Technology Applications, (301) 619-4145. For patent issues, Ms. Leigh Callander, Supervisory Patent Attorney, (301) 619-7808.
In accordance with 35 U.S.C. 209 (e) and 37 CFR 404.7 (a)(1)(i), announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license to United States Patent Application 16/063,877 with an effective filing date of December 21, 2015, entitled “Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases” to the University of Chicago having its principal place of business at 1542 E. 53rd St, 2nd Floor, Chicago, IL 60615.
Anyone wishing to object to grant of this license can file written objections along with supporting evidence, if any, within 15 days from the date of this publication. Written objections are to be filed with the Director, Office of Research and Technology Applications (see ADDRESSES).
In accordance with applicable laws and regulations, the Department of the Army hereby gives notice of its intent to grant a partially exclusive, royalty-bearing, revocable license.
Mr. Paul Michaels, Office of Research and Technology Applications, (301) 619-4145. For patent issues, Ms. Leigh Callander, Supervisory Patent Attorney, (301) 619-7808.
In accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i), announcement is made of the intent to grant a partially exclusive, royalty-bearing, revocable license to United States Patent Application Serial No. 16/327,846 filed on February 24, 2019, from PCT Application No. PCT/US2017/047547, entitled “Real-Time Estimation of Human Core Body Temperature Based on Non-Invasive Physiological Measurements,” and a continuation patent application thereof, to Seaclaid, LLC, a limited-liability company having its principal place of business at 7593 Fenway Rd, New Albany, OH 43054.
Anyone wishing to object to grant of this license can file written objections along with supporting evidence, if any, within 15 days from the date of this publication. Written objections are to be filed with the Command Judge Advocate (see ADDRESSES).
In accordance with applicable laws and regulations, announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license.
Mr. Paul Michaels, Office of Research & Technology Applications, (301) 619-4145. For patent issues, Ms. Leigh Callander, Supervisory Patent Attorney, (301) 619-7808.
In accordance with 35 U.S.C. 209 (e) and 37 CFR 404.7 (a)(1)(i), announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license to United States Patent 9,675,572, filed April 22, 2011, entitled “Intravenous Omega-3 Fatty Acid Compositions and Methods of Use” to Deck Therapeutics Inc. having its principal place of business at 180 Varick Street, 6th Floor, New York, NY 10014.
Anyone wishing to object to grant of this license can file written objections along with supporting evidence, if any, within 15 days from the date of this publication. Written objections are to be filed with the Director, Office of Research and Technology Applications (see ADDRESSES).
In accordance with applicable
laws and regulations, announcement is
made of the intent to grant an exclusive
within a field of use, royalty-bearing,
revocable patent license.
Dr. Paul G. Michaels, eJD, Medical Technology
Transfer Office, (301) 619–4145
In accordance with 35 U.S.C. 209(e) and 37
CFR 404.7(a)(1)(i), announcement is
made of the intent to grant an exclusive
within a field of use, royalty-bearing,
revocable license of US Patent No. 10,058,448 B2
entitled “Arm Immersion Cooling
Apparatus and Method”, issued on August 28, 2018 to First Line Technology
LLC, having its principal place of business at
3656 Centerview Drive, Suite 4, Chantilly,
Virginia 20151.
In accordance with applicable laws and regulations, announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license.
Mr. Paul Michaels, Office of Research & Technology Applications, (301) 619-4145. For patent issues, Ms. Leigh Callander, Supervisory Patent Attorney, (301) 619-7808.
In accordance with 35 U.S.C. 209 (e) and 37 CFR 404.7 (a)(1)(i), announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license to United States Patent 7,494,980, filed March 9, 2004, entitled “Antimicrobial Peptide and Methods of Use Thereof” and United States Patent 8,778,889, filed on October 18, 2006, entitled “Antimicrobial Decapeptide Oral Hygiene Treatment” to P4 Microbiome, Inc. having its principal place of business at 20271 Goldenrod Lane, Suite 2046, Germantown, MD 20876.